December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

14.72 -0.71 (-4.60%)
Official Closing Price Updated: 4:15 PM EDT, Aug 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >
News headline image
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
From Silence Therapeutics plc
Via Business Wire
News headline image
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Where Silence Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Silence Therapeutics ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Present at Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
The Latest Analyst Ratings for Silence Therapeutics ↗
 
Via Benzinga
News headline image
Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate ↗
Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports Second Quarter 2023 Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
News headline image
Earnings Scheduled For August 10, 2023 ↗
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
News headline image
Silence Therapeutics to Present at the Jefferies Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Reports First Quarter 2023 Results
From Silence Therapeutics plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023 ↗
 
Via Benzinga
News headline image
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  Tuesday's session saw 286 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 147 stocks made new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday's session, 149 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 81 companies hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.